|
|
Clinical comparative study of intensity-modulated radiotherapy and gamma knife combined with TACE for the treatment of primary hepatic carcinoma |
ZHANG Yu1,CHEN Shaoshui2,LI Gong1,LIU Changmin2, LI Guangxin3 |
1.Cancer Second Division,General Hospital of Chinese People’s Armed Police Force,Beijing 100039,China; 2.Cancer Division,Affiliated Hospital of Binzhou Medical Oncology,Binzhou 256600,China 3. Cancer Division, Third Hospital of Beijing Municipal Corps,Chinese People’s Armed Police Force, Beijing 100049,China |
|
|
Abstract Objective To compare the clinical curative effect of the gamma knife (γ knife) and intensity-modulated radiotherapy(IMRT) combined with transcatheter hepaticarterial chemoembolization (TACE) for primary hepatic carcinoma.Methods According to the stochastic indicator, 94 cases of PHC patients betweem March 2012 and June 2014 were equally divided into control group and observation group. Patients in control group were treated with intensity-modulated radiotherapy combined with TACE, while observation group was treated with γ knife combined with TACE. The recent and forward curative effect, occurrence of adverse reactions of drugs and the level of serum alpha fetal protein (AFP) of the two groups were analyzed comparatively.Results After one-month treatment, the effective rate of observation group was 82.98% (39/47), which was obviously higher than that of control group[57.45% (27/47)], and the difference was statistically significant (P<0.05). The level of serum AFP of the two groups declined obviously after treatment, and thatof observation group was significantly lower than in control group. The difference was statistically significant (P<0.05 or P<0.01). The incidence of adverse reactions in observation group was 14.89% (7/47), which was significantly lower than in control group[25.53% (12/47)], and the difference was statistically significant (P<0.05). However, the difference of survival rate after 6 months and 12 months of treatment between the two groups was not of statistical significance (P>0.05). The survival rate of observation group after 24 months of treatment was significantly higher than that of control group (P<0.05).Conclusions Compared with intensity-modulated radiotherapy combined with TACE, γ knife combined with TACE for the treatment of primary hepatic carcinoma has a better recent and forward curative effect in that it can not only reduce the incidence of toxic reactions of drugs effectively, but significantly inhibit the level of serum AFP, which is worthy of clinical popularization and application.
|
Received: 02 September 2016
|
|
|
|
|
[1] |
吕 行,赵 强,宁 鹏,等.奥沙利铂和吉西他滨栓塞化疗联合三维适形放疗治疗晚期原发性肝癌疗效观察[J].海南医学,2014,(22):3307-3309.
|
[2] |
彭 巍.射波刀及其联合灌注栓塞化疗治疗原发性肝癌的临床研究[D].广西医科大学,2013.
|
[3] |
Hu B,Wang S S,Du Q.Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: From bench to bedside[J].World J Hepatol,2015,7(9):1209-1232.
|
[4] |
黄 慧,谢从华,龙志雄.伽马刀或三维适形调强放疗联合经皮肝动脉插管化疗栓塞治疗原发性肝癌的疗效观察[J].中国肿瘤临床与康复,2013,20(2):137-139.
|
[5] |
沙晓锋,张 娇,韦淑贞,等.介入联合体部伽玛刀治疗原发性肝癌疗效分析[J].现代肿瘤医学,2013,21(10):2281-2283.
|
[6] |
中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324.
|
[7] |
刘德华,富 韬,罗娅红,等.动脉化疗栓塞与三维适形放疗联合在原发性肝癌患者中应用及效果[J].现代生物医学进展,2013,13(15):2921-2924.
|
[8] |
田 慧,和振坤,徐庆杰,等.TACE联合放疗治疗原发性肝癌的疗效及对生存质量的影响[J].中国老年学杂志,2013,33(20):4987-4989.
|
[9] |
彭生才,袁志平,王 秋,等.肝动脉栓塞化疗联合三维适形放疗治疗中晚期原发性肝癌临床疗效评价[J].西部医学,2013,25(10):1529-1531.
|
[10] |
刘合代,丁 罡,张 明,等.肝动脉栓塞化疗联合放疗治疗原发性肝癌的疗效分析[J].现代肿瘤医学,2015,(9):1258-1261.
|
[11] |
严 程,朱政鸣,孙晓龙,等.伽玛刀联合肝动脉栓塞化疗治疗原发性肝癌的临床疗效观察[J].现代生物医学进展,2015,15(24):4686-4689.
|
[12] |
Chung Y H,Han G,Yoon J H,et al.Intetim analysis of START: Studyin Asia of the combination of TACE (transcatheter arterial chemoem-bolization)with sorafenib in patients with hepatocellular carcinomatrial[J].Int J Cancer,2013,132(10):2448-2458.
|
[13] |
王 民.肝动脉化疗栓塞联合三维适形放射治疗原发性肝癌的临床观察[D].山东大学,2012.
|
[14] |
吴 鹤,应晓珍,吕素珍,等.肝动脉栓塞化疗联合调强放疗治疗原发性肝癌的临床疗效[J].中国现代医生,2015,53(20):51-53.
|
[15] |
韩 冰.伽马刀放疗与肝动脉化疗栓塞联合治疗肝癌伴门静脉癌栓的疗效分析[J].中国继续医学教育,2015,7(23):96-97.
|
[1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(11): 1017-1020. |
|
|
|
|